Klinkhammer, Barbara M. http://orcid.org/0000-0002-1566-7129
Lammers, Twan http://orcid.org/0000-0002-1090-6805
Mottaghy, Felix M. http://orcid.org/0000-0002-7212-6521
Kiessling, Fabian http://orcid.org/0000-0002-7341-0399
Floege, Jürgen
Boor, Peter http://orcid.org/0000-0001-9921-4284
Article History
Accepted: 10 May 2021
First Online: 29 June 2021
Change Date: 5 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41581-021-00464-w
Competing interests
: F.M.M. is an advisory board member for Advanced Accelerator Applications/Novartis and Bayer, holds speaker positions at Siemens, GE Healthcare and Bayer, and receives institutional grants from GE Healthcare and Nanomab. F.K. consults for Merck Darmstadt, holds patents and has running patent applications with Bayer, Roche and Visualsonics, has stock options for Molecular Targeting Inc. and co-owns InVivoContrast GmbH. The remaining authors declare no competing interests.